Phase 1 Trial of ADU-1805
Phase 1
130
about 4.3 years
18+
4 sites in MI, MO, OH +1
What this study is about
Researchers are testing the safety and how the body processes ADU-1805, a drug that targets SIRPα, in adults with advanced solid tumors. The trial will also evaluate if ADU-1805 works better when combined with pembrolizumab.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take ADU-1805
- 2.Take Pembrolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Escalation Phase: Incidence and severity of dose limiting toxicity (DLT), treatment-emergent adverse events (TEAEs), and changes from baseline in safety parameters
Secondary: Escalation and Expansion Phase: Pharmacokinetics of ADU-1805 monotherapy and ADU-1805 plus pembrolizumab, serum concentration-time profile and PK parameters
Oncology